Insmed Incorporated (NASDAQ:INSM) Shares Bought by Values First Advisors Inc.

Values First Advisors Inc. grew its position in Insmed Incorporated (NASDAQ:INSM) by 4.4% during the 4th quarter, Holdings Channel reports. The fund owned 5,199 shares of the biopharmaceutical company’s stock after buying an additional 221 shares during the quarter. Values First Advisors Inc.’s holdings in Insmed were worth $359,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Jennison Associates LLC lifted its position in Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after purchasing an additional 4,560 shares during the period. Capital CS Group LLC purchased a new position in shares of Insmed during the 4th quarter worth approximately $586,000. Orion Portfolio Solutions LLC lifted its holdings in shares of Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after buying an additional 9,170 shares during the period. Ally Bridge Group NY LLC boosted its stake in shares of Insmed by 16.9% in the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after buying an additional 21,833 shares in the last quarter. Finally, Vestal Point Capital LP grew its holdings in Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after acquiring an additional 850,000 shares during the period.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 42,975 shares of Insmed stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $78.61, for a total transaction of $3,378,264.75. Following the completion of the sale, the chief operating officer now directly owns 146,082 shares in the company, valued at $11,483,506.02. The trade was a 22.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the transaction, the insider now directly owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. This represents a 48.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 481,833 shares of company stock valued at $37,345,553 over the last three months. 4.60% of the stock is currently owned by insiders.

Insmed Stock Performance

INSM stock opened at $79.60 on Thursday. The stock’s 50 day moving average price is $73.15 and its 200 day moving average price is $73.16. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $82.04.

Analyst Upgrades and Downgrades

A number of research firms have commented on INSM. Guggenheim raised their target price on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday, February 7th. JPMorgan Chase & Co. increased their price target on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Truist Financial reissued a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Stifel Nicolaus increased their target price on shares of Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $85.60.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.